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II. Abbreviation List 
°C Degree Celsius 
% Percentage 
αSMA α-smooth muscle actin 
ASIR Age-standardized incidence rates 
APS Ammonium persulfate 
ATRA All-trans retinoic acid 
ASMR Age-standardized mortality rates 
AmB Amphotericin B 
Arc Acrylamide 
Ang-II Angiotensin II 
bFGF Basic fibroblast growth factor 
BSA Bovine serum albumin 
Cal Calcipotriol 
caPSCs Cancer-associated PSCs 
CP Chronic pancreatitis 
CRC Colorectal cancer 
CAFs Cancer-associated fibroblasts 
CT Threshold cycle 
CM Conditioned medium 
cpPSCs Chronic pancreatitis-associated PSCs 
CYP24A1 Cytochrome P450 family 24 subfamily A member 1 




DMSO Dimethyl sulfoxide 
DCs Dendritic cells 
DAB 3,3’-diaminobenzidine 
EMT Epithelial-mesenchymal transition 
ECM Extracellular matrix 
FBS Fetal bovine serum 
Gly Glycine 
GEM Gemcitabine 





HSCs Hepatic stellate cells 




mmol/L Millimoles per liter 
µL Microliter 
mAb Monoclonal antibody 





nPSCs Normal PSCs 
OS Overall survival 
PCN Penicillin 
PDAC Pancreatic ductal adenocarcinoma 
PC Pancreatic cancer 
PBS Phosphate-buffered saline 
PCCs Pancreatic cancer cells 
PFS Progression-free survival 
PSCs Pancreatic stellate cells 
PDGF Platelet-derived growth factor 
qRT-PCR Quantitative real-time polymerase chain reaction 
s Second 
STR Streptomycin 
SHH Sonic hedgehog 
SDS Sodium dodecyl sulfate  
SDF-1 Stromal cell-derived factor 1 
SSc Systemic sclerosis 
SD Standard deviation 
RT Room temperature 
TNF-α Tumor necrosis factor-α 
TME Tumor microenvironment 





VDR Vitamin D receptor 
V Volt 
VEGF Vascular endothelial growth factor 
WH Wound healing 






As a gastrointestinal malignancy with poor clinical outcomes[1], pancreatic cancer (PC) 
takes place when pancreatic cells grow out of control, develop into a lump and acquire 
the ability to invade other organs of the body[2, 3]. About 85% of PC is pancreatic ductal 
adenocarcinoma (PDAC)[4, 5]. The severe fibrogenic stroma reaction in PDAC 
enhances tumor progression and increases chemotherapy resistance[6-8]. Pancreatic 
stellate cells (PSCs), major producers of extracellular matrix (ECM), are known to 
participate in the stroma/desmoplasia reaction in PDAC and chronic pancreatitis (CP). 
Recently, targeting PSCs has emerged as a promising strategy for PDAC therapy[8, 9]. 
Many pieces of research have indicated that Vitamin D receptor (VDR) could reverse 
stroma fibrosis in many diseases, while little is known about its anti-PSCs effect in 
PDAC[10-14]. Therefore, this project is conducted to explore the role of a VDR ligand in 
the activation of PSCs and PSCs-augmented tumor progression in PDAC.  
1.1. Epidemiology of PDAC 
According to the estimates from GLOBOCAN 2018, PDAC ranks as the 11th most 
common carcinoma worldwide. Additionally, as the 7th primary cause of carcinoma 
mortality, PDAC caused 432,242 deaths in 2018[15]. The age-standardized incidence 
rates (ASIR) and morality rates (ASMR) differ significantly between regions, shown in 
Figure 1[15, 16]. Compared to women, the incidence of PDAC in men is slightly higher[15]. 
Despite increased awareness of the potential risk factors for PDAC and new early 
diagnostic tools, the incidence of PDAC is estimated to rise. According to the report of 
GLOBOCAN 2018, 355,317 new cases are expected to be diagnosed by 2040[15]. Until 
now, causes of PDAC are complex and not yet adequately recognized. However, 




diabetes, family history, Helicobacter pylori infection, and CP [3, 17, 18]. The prognosis of 
PDAC is especially poor, as usually 24% of patients survive one year and 9% survive 




Figure 1: Maps indicate ASIR (up panel) and ASMR (low panel) for global PC in 2018 





1.2. PSCs in the tumor microenvironment (TME) of PDAC 
The poor prognosis of PDAC is attributed to several reasons, among which the highly 
desmoplastic TME is the primary cause of treatment failure of conventional 
chemotherapy[19-21]. The TME, also known as the PDAC stroma, containing ECM, 
PSCs, endothelial cells, collapsed vessels, and immune cells, is reported to account 
for most PDAC volume[22, 23]. Constituting approximately 50% of the TME, PSCs have 
been considered one of the most prominent cell types of PDAC and have received 
great attention in recent decades[24-36].  
1.2.1. Brief introduction of PSCs 
About one century after Karl von Kupffer discovered hepatic stellate cells (HSCs) in 
1876, similar star-shaped cells in the pancreas were found in 1982[37]. The in-vitro 
isolation and culture methods were not established until 1998[38, 39]. From then on, 
emerging research has focused on this new field, and PSCs are now well known as 
the leading cause of the stromal/desmoplasia reaction, which is the typical CP and 
PDAC[6, 40-42].  
Located in peri-acinar or interlobular regions of the normal pancreas, PSCs are in 
quiescence, with many perinuclear droplets and low capacity to produce ECM[38, 39]. In 
diseases like PDAC or CP, quiescent PSCs get activated and change to a 
myofibroblast phenotype[43, 44]. Activated PSCs show positive immunostaining of α-
smooth muscle actin (αSMA), no intracellular lipid droplets, enhanced release of 
numerous molecules, elevated migration and proliferation ability, and high ECM protein 
production[43, 44]. Figure 2 is a schematic diagram of the PSCs’ activation procedure 
and PSCs-PCCs crosstalk. The following sections will focus on the main ways in which 






Figure 2: Schematic diagram of PSCs activation procedure and PSCs-PCCs crosstalk. 
PCCs induce PSCs transformation from quiescent to activated status by paracrine stimulation. 
Activated PSCs release various molecules, which in turn promote the aggressiveness of PCCs. 
In addition, PSCs remain activated, showing increased migration, proliferation, and ECM 









1.2.2. PSCs enhance ECM secretion and reprogram TME in PDAC 
PSCs augment PDAC aggressiveness by causing chemoresistance via the severe 
stroma/desmoplasia reaction, which is attributed to the abundant ECM proteins 
secreted by PSCs[45]. This reaction also results in hypoxia in the tumor, epithelial-
mesenchymal transition (EMT), enhanced malignant behavior of cancer, and 
chemoresistance[45]. PSCs were reported to improve the malignant behavior of PDAC 
by overproducing ECM proteins which regulate the phenotype of PDAC cells via the 
FAK/β1 integrin pathway[46].  
The deposited ECM proteins form a dense barrier that inhibits chemotherapy drug 
delivery to PCCs via blood vessels[47]. The high ECM secretion also leads to increased 
pressure in pancreatic cancer[48], which contributes to vascular atrophy, insufficient 
blood flow, and depletion of nutrients[49]. Researches indicated that PSCs-PCCs 
crosstalk supported PDAC aggressiveness in the nutrient-depleted and hypoxic TME[50, 
51]. Furthermore, exosomes secreted by PSCs are abundant in cellular metabolites like 
amino acids and palmitate, which fuel the tricarboxylic acid cycle in PDAC, thereby 
accelerating PDAC progression in the nutrient-depleted TME[52].  
1.2.3. PSCs increase chemoresistance in PDAC 
In addition to forming a physical barrier for chemotherapy drugs, PSCs increase 
chemoresistance by releasing numerous molecules, which play essential roles in the 
chemoresistance of PDAC cells[27, 49, 53]. For instance, periostin released by PSCs, 
keeping PSCs activated in an autocrine way, enhances the gemcitabine (GEM) 
resistance and invasion of PDAC cells via ERK1/2 and FAK/AKT pathway[54]. 
Furthermore, PSCs-secreted SDF-1α enhances resistance to GEM via ERK1/2 and 
FAK/AKT pathway in PDAC cells[55]. A recent study indicates that PSCs-derived 




1.2.4. PSCs enhance metastasis in PDAC   
The recent finding revealed that PSCs enhanced metastasis in PDAC by initiating EMT 
in PDAC cells[57]. Also, Schnittert et al. indicated that PSCs overexpressed integrin α11 
and increased PSCs-augmented PDAC metastasis via paracrine TGF-β[58]. 
Researches also demonstrated that PSCs induced EMT, a well-known procedure of 
cancer metastasis initiation, in PDAC cells[57, 59]. Qian et al. revealed that galectin-1-
overexpressed PSCs increased PDAC invasion and migration by secreting paracrine 
SDF-1 through the NFκB pathway[60].  
1.2.5. PSCs facilitate immune tolerance in PDAC 
Several studies indicated that PSCs significantly impacted immune tolerance in 
PDAC[61-64]. PSCs were reported to highly secret TGF-β1 and IL-10, which suppresses 
dendritic cells (DCs), thus impeding immune responses in PDAC[65]. Additionally, one 
study suggested that MDSCs might be stimulated to differentiate and expand by PSCs 
via IL-6/STAT-3 signaling and form a TME resistant to immunotherapy[49, 66]. 
Furthermore, PSCs reduced CD8+ T cells infiltration of the stromal juxtatumoral 
compartment, thereby hindering their access to PDAC cells[67].  
1.3. Current progress in PSCs-targeting strategies  
Although the field of PSCs is young, researchers have put up with several strategies 
to eliminate PSCs and reprogram TME by targeting PSCs or targeting the ECM 
production directly[26, 54, 60, 68-71]. A summary is shown in Table 1. The following parts will 




1.3.1. Targeting tumor-originated sonic hedgehog (SHH) signaling 
pathway 
PDAC cells are found to support stroma by the SHH pathway in a paracrine way[72]. An 
SHH inhibitor, IPI-926, combined with GEM could increase the vascular density and 
gemcitabine concentration in PDAC[72, 73]. However, an in-vivo study indicated that 
tumors from SHH-deleted PDAC mice showed a more invasive tumor behavior despite 
decreased stroma[74]. Therefore, the clinical trial of IPI-926 (phase II) was withdrawn 
because of increased mortality[75]. Similarly, in another in-vivo study, depletion of 
myofibroblasts in transgenic mice leads to more invasive and undifferentiated PDAC 
with reduced survival[76]. These works suggest that stroma functions are multifaced and 
simply deleting the whole stroma might result in the loss of fibrotic barriers that have 
an inhibitory function of metastasis. Therefore, current strategies have changed from 
simple stroma deletion to TME reprogramming or modulation with more beneficial 
outcomes[77-80]. 
1.3.2. Reprogramming strategies for PSCs 
Many pieces of research have focused on reprogramming PSCs, reducing the 
activated state to reduce PSCs-augmented PDAC progression[79-81].  
Previous studies indicated that Vitamin A analog was able to reprogram PSCs. For 
example, all-trans retinoic acid (ATRA) treated PSCs exhibited diminished activation, 
thereby leading to less behavior of PDAC cells[80, 82, 83]. Furthermore, an in-vivo study 
showed that PSCs were deactivated when treated by gold nanoparticles, which 
delivered ATRA plus heat-shock protein 47 siRNA, thereby improving GEM delivery to 
tumors in the mouse model of PDAC[84]. However, clinical trials on vitamin A analog 
showed disappointing outcomes. A pilot phase II trial in England indicated that drug 




unresectable PDAC[85]. Another Pilot phase II trial in the USA also showed that drug 
combination (13-cis-RA plus interferon-α) displayed no anti-tumor effects on PDAC[86].   
Pirfenidone has been shown to reduce PSCs activation, collagen secretion, and 
periostin, thereby attenuating proliferation and metastasis in the PDAC mouse 
model[87]. Compared to treatment with GEM alone, pirfenidone plus GEM diminished 
tumor progression by deactivating PSCs[87]. In another PDAC research, pirfenidone 
plus N-acetyl cysteine decreased fibrotic reaction, cancer cell growth, and metastasis 
in a hamster model[88]. 
Attempts were also made in reprogramming PSCs by miRNAs, which is a potential 
therapeutic target[89]. miRNA-29 was found to be reduced in activation procedure PSCs 
in PDAC[90]. Restoring miRNA-29 expression in PSCs reduced desmoplasia reaction 
and PDAC aggressiveness[90]. A recent study indicated that miRNA let-7d impeded 
PSCs activation by targeting thrombospondin 1 and subsequently decreased 
pancreatic fibrosis[91]. 
Some other promising targets are also reported recently. The endogenous lipid Lipoxin 
A4 is demonstrated to impede the activation procedure of PSCs, which causes 
decreased tumor volume and aggressiveness in vivo[78]. Additionally, galectin-1 is 
upregulated in PSCs and correlated with dismal clinical outcomes of PDAC[60]. 
Galectin-1 deleted mice showed a reduced PSCs activation, enhanced T cell infiltration, 
and attenuated metastasis of tumor[92]. 
1.3.3. Strategies targeting stromal ECM production 
As described in section 1.2.2., the high solid stress caused by PSCs-released ECM is 
closely correlated with chemoresistance. Therefore, several pieces of research have 




GEM combined with PEGPH20, a drug based on the recombinant human 
hyaluronidase (HA) enzyme, was found to promote survival and reduce the malignant 
behavior of tumors in the PDAC mice model[93]. A Phase I trial also indicated promising 
outcomes that patients treated with PEGPH20 plus GEM showed prolonged overall 
and progression-free survival (OS and PFS) rates [94]. Moreover, the phase II trial drug 
combination (PEGPH20+nab-paclitaxel+GEM) showed increased PFS in patients with 
high-HA PDAC[95]. 
Angiotensin II (Ang-II) was found to promote proliferation and ECM production of 
PSCs[81]. Therefore, the angiotensin blockers are of the therapeutic potential, and two 
Ang-II type I receptor inhibitors were investigated. Olmesartan reduced collagen I 
production of PSCs and impeded tumor growth in the PDAC mouse model[96]. The 
other inhibitor, losartan, decreased pressure in tumors and increased vascular 
perfusion by reducing collagen and HA production in PSCs, which improved 
chemotherapy in PDAC mouse models[97]. 
 
Table1 Strategies targeting PSCs in TME of PDAC  
Strategies Main results 
Clinical studies 
PEGPH20 Phase Ib: Elevated OS and PFS in PDAC patients[94]. 




Marimastat Phase II: No extra benefits were found in PDAC patients compared to GEM 
alone[98]. 
ATRA Phase Ib: Ongoing, no results released[99]. 
Preclinical studies 
IPI-926 elevated vascular density and concentration of GEM in tumor of KPC mice[73]. 
Minnelide reduced ECM production, increased vasculature, improved drug delivery in 
tumors in both spontaneous KPC mice and PDAC xenograft mice[100]. 




Resulted in more aggressive tumors, increased hypoxia, EMT, and reduced 
survival in transgenic PDAC mice, which deleted αSMA+ cells[76]. 
SHH deletion Led to undifferentiated malignancies, increased vascularity, and proliferation in 
SHH-deleted PDAC mice[74]. 
PEGPH20 Depleted HA, expanded blood vessels, and increased chemotherapeutic drug 
delivery in tumors of PDAC mice[48]. 
Pirfenidone Reduced PSCs proliferation, collagen production; co-treatment with GEM 
reduced tumor growth and hepatic metastasis in PDAC mice[88]. 
Olmesartan Decreased PSCs proliferation, αSMA expression, collagen I production, tumor 




Losartan Decreased stress in solid tumors, improved vascular perfusion, increased 
chemotherapeutic delivery in PDAC mice[97]. 
ATRA Decreased PSCs migration, collagen synthesis, leading to increased apoptosis 
of surrounding PSCs[80]. 
Calcipotriol Improved intratumoral concentration of a chemotherapeutic drug, decreased 
tumor size, prolonged survival compared to GEM alone in KPC mice[79]. 




Reduced PSC activation, decreased collagen deposition, increased GEM 
delivery, improved OS in PDAC mice model[69]. 




reduced desmoplasia, decompressed blood vasculature, improved GEM 
efficacy in patient-derived xenograft tumor models[29]. 








1.4. Anti-fibrosis role of VDR and its ligands in diseases  
1.4.1. VDR and its ligands in targeting myofibroblasts of non-cancer 
fibrotic diseases 
In several non-cancer fibrotic diseases, VDR and its ligands have been widely 
investigated. Several studies have demonstrated that VDR ligands mainly target 
myofibroblasts and impede the pro-fibrotic function of TGFβ[104-107]. For instance, in 
hepatic fibrosis, quiescent HSCs were activated by the TGFβ1/SMADs pathway and 
changed to an activated state, which produced abundant ECM proteins[108, 109]. In a 
study using carbon tetrachloride mouse model of hepatic fibrosis, treatment with VDR 
ligands deactivated HSCs and abolished hepatic fibrosis, while VDR-knockout led to 
spontaneously developed liver fibrosis[14]. As to the mechanism, TGFβ1 signaling 
redistributes the VDR-binding sites in HSCs[14]. VDR ligands induce VDR to bind to the 
SMAD3 pro-fibrotic genes, which reduces the binding of SMAD3 at these sites, thereby 
inhibiting fibrosis[14]. Similar results were found in another research indicating that rat 
HSCs treated with vitamin D (VD) show reduced fibrosis by impeding the promoter 
activity of collagen 1α[110]. In a study of systemic sclerosis (SSc), a disease with 
excessive accumulation of ECM contents, researchers showed that VDR induction by 
its ligand decreased the stimulating effects of TGFβ on fibroblasts differentiation into 
myofibroblast, thereby preventing collagen production and fibrosis in the SSc mouse 
model[111]. Besides, VDR ligand was shown to inhibit the TGFβ1-intermediated pro-
fibrotic effect in human primary cardiac fibroblasts[112]. Furthermore, VDR ligand 
treatment prevented bleomycin-generated lung fibrosis in a mouse model of idiopathic 




1.4.2. VDR and its ligands in targeting cancer-associated fibroblasts 
(CAFs) 
Unlike those in non-cancer diseases, not many studies about the relationship between 
VDR and CAFs are found, and it remains a new area to be studied. In colorectal cancer 
(CRC), investigations have demonstrated that VD diminished tumorigenesis in animal 
models of CRC[113], and VD deficiency is correlated with an elevated risk of CRC[114-
116]. Higher VDR expression in CAFs was related to a longer OS in CRC patients, and 
VDR ligand showed a protective effect against CRC by reprogramming CAFs[117]. 
Sherman et al. showed that VDR ligand could decrease inflammation and enhanced 
the intratumoral concentration of GEM in the PDAC mouse model[79]. Moreover, Kong 
et al. demonstrated that VDR induction by its ligand in pancreatic CAFs inhibited 
exosomal miR-10a-5p secretion, an oncomiRNA, thus reducing its tumorigenic effects 
on PDAC cells[118]. However, detailed mechanisms by which VDR modulates CAFs and 
tumor-stroma crosstalk remained to be clarified. 
Since fibrotic stroma is essential in tumor progression, the VDR-intermediated 
remodeling of stroma might be a promising therapeutic method to enhance 









1.5. Objectives of this Project 
The general purpose of our project is to obtain a deeper understanding of VDR in PSCs 
activation and tumor-stroma crosstalk. For this purpose, the following questions are to 
be explored: 
a). Establishment and verification of the isolation of both quiescent PSCs and activated 
PSCs.  
b). How is the expression of VDR respectively in tumor cells and caPSCs isolated from 
human samples?  
c). Can VDR induction by its ligand inhibit the activation of PSCs?  
d). To what extent does the modulation of VDR in caPSCs influence the tumorigenic 





2. Materials and Methods 
2.1. Materials 
2.1.1. Apparatus 
Autoclave Unisteri, Germany 





Cell culture incubator Binder, Germany 
Combitips Plus Sigma-Aldrich, US 
Cool centrifuge Eppendorf, Germany 
CO2 Incubator Binder, Germany 
CO2 Incubator Thermo Fisher Scientific, US 
Micro centrifuge Labtech, Germany 
Microwave oven Siemens, Germany 
DNA workstation Uni Equip, Germany 
Drying cabinet Heraeus, Germany 
Electronic pH meter Knick, Germany 
Fluorescence Microscope Zeiss, Germany 
Hypercassette Amersham Biosciences, Germany 




Lamina flow Hereaus flow laboratoies, Germany 
Liquid nitrogen tank MVE, US 
Microscope Olympus, Germany 
Micro weigh Chyo, Germany 
Microplate reader VERSA max, Germany 
Mini electrophoretic transfer cell 
 
Bio-Rad, Germany 
Multipette Plus Eppendorf, Germany 
Nanodrop 2000 Thermo fisher scientific, US  
Pipettes Sigma-Aldrich, US 
Pipette controller Eppendorf, Germany 
Power supply power pac 300 Bio-Rad, Germany 
DNA workstation Uni Equip, Germany 
Shaker Edmund Buehler, Germany 
Step one PCR system Applied Biosystems, Germany 
Thermocycler Eppendorf, Germany 
Thermomixer comfort Eppendorf, Germany 
UV illuminator Labortechnik, Germany 
Vortex Labnet, Germany 
Water bath Memmert, Germany 




X cell II TM Blot module Invitrogen, Germany 
Fridge (4°C, -20°C, -80°C) Siemens, Germany 
2.1.2. Computer Software and Hardware 
Endnote X9 Clarivate Analytics, US 
GraphPad Prism Version 7.0, US 
Image J National Institutes of Health, US 
SPSS Version 21, US 
 Hardware HP, US 
  
2.1.3. Experimental consumables 
Blot paper Bio-Rad, Germany 
Cell flasks (T25, T75, T125) Thermo Fisher Scientific, Denmark 
Cell scrapers Sigma-Aldrich, Germany 
Cell strainer (40µm, 70µm, 100µm) BD Bioscience, US 
Disposable safety scalpels #22 Thermo Fisher scientific, Germany 
10µl T.I.P.S. Eppendorf, Germany 
20µl T.I.P.S. Eppendorf, Germany 
100µl T.I.P.S. Eppendorf, Germany 




1mL T.I.P.S. Eppendorf, Germany 
Film ECL GE healthcare, Germany 
15mL Falcon tube TPP, Switzerland 
50mL Falcon tube Corning, Mexico 
Filters 0.25µm Sartorius, Germany 
Filters 0.45µm Sartorius, Germany 
Glass cover slips Thermo Fisher Scientific, Germany 
Green gloves SHIELD Scientific, Netherlands 
Glass slides Thermo Fisher Scientific, Germany 
Hydrophobic pen Dako, Denmark 
Immobilon-PSQ PVDF transfer membrane Sigma-Aldrich, Germany 
Orange gloves SHIELD Scientific, Netherlands 
Plates (6-, 12-, 24-, 96-well) Thermo Fisher scientific, Denmark 
5mL Pipette Costar, US 
10mL Pipette Costar, US 
25mL Pipette Costar, US 
50mL Pipette Costar, US 





2.1.4. Chemical reagents and buffers 
Amphotericin B (AmB) solution Sigma-Aldrich, DE 
Ammonium persulfate (APS) Serva, US 
Bovine Serum Albumin(BSA) Biomol,DE 
β-Mercaptoethanol Sigma-Aldrich, DE 
Collagenase P Roche, DE 
Crystal violet Sigma-Aldrich, DE 
CaCl2·2H2O Merck, DE 
 Calcipotriol (Cal) Sigma-Aldrich, DE 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, DE 
DNase Roche, DE 
Dulbecco’s modified Eagle medium (DMEM) Gibco, US 
D-(+)-Glucose Sigma-Aldrich, DE 
DMEM/F12 Gibco, US 
EDTA Calbiochem, DE 
ECLTM Western blotting system Amersham Biosciences, DE 
70% Ethanol Apotheke GH, DE 
96% Ethanol Apotheke GH, DE 
>99% Ethanol Apotheke GH, DE 




Glycine (Gly) Roth, DE 
IC Fixation buffer Thermo Fisher Scientific, DE 
Isopropanol Roth, DE 
KCl Serva, DE 
KH2PO4 Sigma-Aldrich, DE 
Loading buffer 4X Bio-Rad, USA 
Methyl cellulose Sigma-Aldrich, DE 
MgCl2·6H2O Fluka, Switzerland 
MgSO4·7H2O Merck, DE 
Milk powder Roth, DE 
NaHCO4·2H2O Merck, DE 
NaCl Sigma-Aldrich, DE 
Nycodenz Axis-shield PoC, Norway 
NaHCO3 Sigma-Aldrich, DE 
phosphate-buffered saline (PBS) PAN-Biotech, DE 
Penicillin-Streptomycin (PCN-STR) Mixture  Lonza, US 
Permeabilization Buffer 10X Thermo Fisher Scientific, DE 
4% PFA Pharmcy, DE 
37% PFA Applichem, DE 




Pronase Roche, DE 
Protease from stretomyces griseus Sigma-Aldrich, US 
Standard proteins Bio-Rad, US 
Protease inhibitor cocktail Roche, DE 
RPMI 1640  Gibco, US 
RNase-free water  Qiagen, DE 
RIPA lysis buffer 10X Millipore, DE 
Sodium dodecyl sulfate (SDS) Roth, DE 
Trypan blue Sigma-Aldrich, DE 




Trypsin EDTA Lonza, Switzerland 
Tris base Bio-Rad, US 
Tween 20 Sigma-Aldrich, DE 
Verse Solution Gibco, US 
  
2.1.5. Kits and Primers 
BCA protein kit Thermo Fisher Scientific, DE 




cDNA Synthesis kit Bio-Rad, US 
ImmPACT DAB Peroxidase substrate kit VECTOR, DE 
Matrixgel Matrix Corning, DE 
QuantiTect Reverse Transcription Kit Qiagen, DE 
QuantiTect Primer Assay (200) Qiagen, DE 
RNeasy Micro Kit Qiagen, DE 
Sso Fast Eva Green Bio-Rad, DE 
Polyester Membrane Cell Culture Inserts Corning, DE 
ACTB Qiagen, DE 
αSMA Qiagen, DE 
Cytochrome P450 family 24 subfamily A 
member 1 (CYP24A1) 
Qiagen, DE 
GAPDH Qiagen, DE 
VDR Qiagen, DE 
  
2.1.6. Antibodies 
Antibody  Source 
Horseradish peroxidase (HRP)-linked anti-
rabbit IgG 
Cell signaling Technology (CST), DE 
Vitamin D3 (D2K6W) receptor Rabbit 





α-Smooth muscle actin Ab CST, DE 
GAPDH antibody (FL-335) Santa Cruz Biotechnology, DE 
GAPDH (D16H11) XP Rabbit mAb CST, DE 
IRDye (800CW, 680RD) goat anti-rabbit Ab LI-COR, US 
Anti-human Desmin Clone D33  
Mouse mAb 
Dako, Denmark 
HRP-conjugated goat anti-mouse IgG Santa Cruz Biotechnology, DE 
Anti-human smooth muscle actin  




2.2.1. Primary PSCs Separation and Culture 
Activated PSCs were separated employing the outgrowth method[39], employing 
surgically resected pancreas tissues from patients with PDAC or CP. Briefly, after 
removing the adipose and connective sections, tissue blocks were sliced into tiny 
fragments (0.5-1mm3) with scalpels and were grown in six-well plates (5-10 
pieces/well). A complete fresh medium containing 20% FBS (Table 2) was added. The 
tissue pieces were then kept in the incubator (37°C, humidified atmosphere, 5% 
CO2/air), and the medium was refreshed after one day. PSCs emerged from tissue 
blocks 3-5 days later, and tissue fragments were eliminated as PSCs reached a 20% 
confluence, and the medium was renewed twice every week. PSCs were harvested 
and cryopreserved in liquid nitrogen when they were 80% confluent. 
Human quiescent pancreatic stellate cells (PSCs) were separated with the Nycodenz 
density gradient method developed by Apte et al. [38, 119]. In brief, adjacent normal 




removing fatty and connective tissue, the tissue was minced to pieces and added with 
20mL enzyme solution and 20µL DNase solution (Table 2) for incubation (120 
cycles/min, 37°C, 15min). Hereafter, it was filtered by a nylon mesh (100µm), followed 
by washing twice with GBSS+NaCl solution (Table 2). Cells were resuspended using 
9.5mL BSA solution and 8mL Nycodenz solution (Table 2), followed by a 20min 
centrifugation at 1400g (4°C). Over the above two solutions interface, the fuzzy band 
was collected in BSA solution and cultured with the complete medium. PSCs were kept 
in the incubator under standard culture conditions. PSCs were collected for culture or 
kept in liquid nitrogen after reaching an 80% confluence.  
Cell type was verified using immunocytochemical staining for PSCs markers (αSMA, 
desmin) as described in section 2.2.5. by immunocytochemistry (ICC). PSCs 
morphology as described by Apte and Bachem[38, 39]. 
Table 2 Solution formula in PSCs isolation and culture 
Solution Chemicals Doses 
MgSO4 solution MgSO4·7H2O 0.7g 
 DIW 100mL 
KH2PO4 solution KH2PO4 3g 
 DIW 100mL 




 DIW 100mL 
Na2HPO4 solution Na2HPO4·2H2O 1.5g 
 DIW 100mL 
MgCl2 solution MgCl2·6H2O 2.1g 
 DIW 100mL 
CaCl2 solution CaCl2·2H2O 0.0334g 
 DIW 100mL 
DNase Solution DNase 10μg 
 DIW 1mL 
GBSS+NaCl solution NaHCO3 0.5675g 
 D-(+)-Glucose 0.25g 
 NaCl 1.75g 




 MgSO4 solution 2.5mL 
 KH2PO4 solution 2.5mL 
 KCl solution 2.5mL 
 Na2HPO4 solution 2.5mL 
 MgCl2 solution 2.5mL 
 CaCl2 solution 2.5mL 
GBSS-NaCl solution NaHCO3 0.1135g 
 D-(+)-Glucose 0.05g 
 MgSO4 solution 500μL 
 KH2PO4 solution 500μL 
 KCl solution 500μL 
 Na2HPO4 solution 500μL 




 CaCl2 solution 500μL 
 DIW 47mL 
Enzyme solution Collagenase P 26mg 
 Pronase  20mg 
 GBSS+NaCl solution 20mL 
0.3% BSA solution BSA 0.15g 
 GBSS+NaCl solution 50mL 
Nycodenz solution (28.7 %) Nycodenz 2.87g 
 GBSS-NaCl solution 10mL 
Complete medium (20%) DMEM/F12 200mL 
 PCN 25000 units 
 STR 25mg 




 FBS 50mL 
Complete medium (10%) DMEM/F12 180mL 
 PCN 20000 units 
 STR 20mg 
 AmB 500μg 
 FBS 20mL 
 
2.2.2. PCCs Culture 
Human PCCs (AsPC-1, MIA PaCa-2, PANC-1) were kept by the biobank of our lab and 
originally from American Type Culture Collection. PCCs were cultivated using 
RPMI1640 (10% FBS). PCCs were detached employing 0.025% Trypsin/EDTA 
solution and passaged every two to four days according to cell growth. PCCs were 
maintained in the incubator under standard culture conditions 
2.2.3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.2.3.1 RNA extraction  
After washing cells with PBS three times, RNA extraction was operated following the 




solution. After mixing, the lysate was pipetted to columns arranged within collection 
tubes, followed by centrifugation (2min, 16000g). 350µl ethanol (70%) was pipetted 
into lysate and mixed. The mixture was pipetted to new columns in new tubes, followed 
by centrifugation (15s, 8000g). Flowthrough was abandoned, then 350µl RW1 was 
pipetted into each column, followed by centrifugation (15s, 8000g). After removal of 
flowthrough, each membrane of the column was added with 80µl DNase I mix, followed 
by a 15min incubation at room temperature (RT). Afterward, each column was added 
of 350µl RW1, followed by centrifugation (15s, 8000g). 500µl RPE was pipetted into 
columns arranged into clean tubes, followed by centrifugation (15s, 8000g). After 
removal of flowthrough, the column was added with 500µl 80% ethanol, followed by 
centrifugation (2min, 8000g). Columns were changed to new tubes, followed by 
centrifugation (5min, 16000g). Hereafter, columns were placed in tubes, and 14µl 
RNase-free water was pipetted onto membranes. Finally, after a 1min centrifugation at 
16000g, RNA was achieved and kept in a -20°C fridge. 
2.2.3.2 Reverse transcription and cDNA pre-amplification 
All reagents, like Quantiscript RT and RT Primer Mix, were kept at RT before use, and 
RNA was thawed on ice. For eliminating genomic DNA, tubes containing the mix (11μL 
template RNA, 2μL Wipeout buffer, 1μL RNase-free water) were arranged in 
Thermomixer (42°C, 2min), then immediately placed in the ice box. Hereafter, the mix 
was pipetted to each tube with another mix (1µl RT Primer Mix, 4µl Quantiscript RT 
Buffer, 1µl Quantiscript Reverse Transcriptase), followed by incubation (15min, 42°C) 
for reverse transcription. To inactivate the transcriptase, another 3min incubation (95°C) 
of tubes was applied. Finally, cDNA was then prepared directly for experiments or kept 




2.2.3.3 qRT-PCR array using the SYBR green method 
qRT-PCR allows the PCR progress to be examined during its execution. The 
fluorescence detection includes an intercalating reagent (SYBR Green I) which 
fluoresces as it bounds to double-stranded DNA. The DNA-SYBR Green complex is 
stimulated at 494nm, then releases green light at 520nm. The quantitative 
determination of target DNA is realized by examining the fluorescence. A total of 42 
PCR cycles consisting of an initial denaturation cycle (95°C, 5min), 40 cycles for primer 
hybridization (95°C, 10min) and elongation (60°C, 30min), and a melting cycle (heated 
from 60 to 95°C within 6min). The fluorescence is detected at the end of the elongation 
phase in each of the 40 primary cycles. The fluorescence increases in proportion to 
the PCR reaction and can thus be used to evaluate the amount of the corresponding 
nucleic acids. A threshold for the level of fluorescence is set, and a threshold cycle (Ct) 
means the number of cycles at which fluorescence reaches a threshold. Besides, the 
GAPDH gene is determined as the reference gene to make relative quantification 
possible. ΔCt is the difference of CtGAPDH to Ct value of the target gene. Relative values 
of target genes are calculated using 2-ΔCt, since the DNA doubles for each cycle at 100% 
amplification efficiency, which is an exponential multiplication. 
2.2.4. Proliferation Assay  
Proliferation detection was conducted applying a commercially available EZ4U kit, a 
modified MTT assay. To be short, PSCs or PCCs (1x104 cells/well) were cultured using 
a complete medium (200μL/well). One day after seeding, new medium with different 
treatments was applied to replace the old one. For the PSCs proliferation testing, PSCs 
were pretreated with 100nM Cal or DMSO for 48h. For PCCs proliferation testing, 
PCCs were cultured with the conditioned medium of cancer-associated PSCs 




substrate, followed by a three h incubation. A microplate reader, setting at 450nm, was 
applied to determine the absorbance.  
2.2.5. Immunocytochemistry (ICC)  
Standard ICC protocol was followed to stain the cells using the mouse mAb against 
desmin or αSMA. Briefly, 4% paraformaldehyde-fixed PSCs (treated with or without 
100nM calcipotriol) slides were rinsed twice using PBS and soaked within 1.5% 
H2O2/PBS solution for 15min in the dark. Following two 5min PBS washes on a shaker, 
slides were incubated with 5% BSA into each well to block at 4°C for 12h in a humid 
atmosphere. Slides were incubated using mouse primary mAb against desmin and 
αSMA (1h, RT). Following another three washes, slides got incubated using HRP-
linked secondary Ab (1h, RT). After washing, they were incubated applying 3,3’-
diaminobenzidine (DAB) and immediately washed with PBS twice after color 
development. Counterstaining was conducted using hematoxylin for 30s, followed by 
two PBS washes. Cover slips with a Dako pen and observe slides under a light 
microscope.  
2.2.6. Wound Healing (WH) Test 
For investigation of PSCs migration ability, a standard WH test protocol was applied. 
Briefly, PSCs (5x105 cells/well) were grown in plates until 100% confluence under 
standard culture conditions. Utilizing a 200μL tip, cell monolayers were scratched 
manually through the center of each well, eliminating cells from an area with about 
0.5mm width. After two washes, PSCs were removed of cellular debris and cultured 
within fresh medium with or without 100nM calcipotriol. Photos were taken every 12h 
within 60h under a light microscope (magnification: 100x). The wound area was 




2.2.7. Migration and Invasion Assessment 
Migration and invasion were tested by conducting experiments applying transwell 
chambers in the absence or presence of Matrigel. For PSCs migration investigation, 
PSCs were firstly cultured in the medium with 1% FBS for 24h. 5x104 PSCs were then 
suspended in 200μL medium (with or without 100nM calcipotriol) and pipetted into 
each upper chamber. For each lower chamber, 600μL DMEM/F12 with 5% FBS was 
arranged as a chemoattractant. As to PSCs-PCCs coculture, PSCs (1x105 cells) 
treated with or without 100nM Cal were grown in each lower chamber. 24h after 
seeding, fresh medium was applied to replace the old. PCCs (5x104 cells) with 200μL 
medium were pipetted into each upper chamber. The incubation time of migration or 
invasion experiments is 24h and 48h, respectively. Hereafter, cells staying on the upper 
side of the membrane were eliminated manually. Besides, crystal violet was utilized to 
stain the cells which invaded or migrated to the lower side. Quantitative determination 
was done by calculating cells within ten random fields using a light microscope 
(magnification 200x).  
2.2.8. Western Blot (WB) 
2.2.8.1 Extraction of proteins from adherent cells 
After three PBS washes, cells were added with RIPA lysis solution. Using cold plastic 
scrapers, cells were scraped and further collected into microfuge tubes. After 30min 
agitation, microfuge tubes were centrifuged (16000g, 20min, 4°C). Finally, new tubes 
were applied to collect supernatant and placed in an ice box. 
2.2.8.2 Quantitation of protein 




manufacturer´s protocol, standard or target proteins (25µl) were arranged into every 
well. Afterward, a 200µl reagent mixture (reagent A: reagent B=50:1) was pipetted into 
each well. Hereafter, the plate was agitated carefully on a shaker for 30s. Following 
incubation (37°C, 30min), absorbance (562nm) was detected by applying a plate 
reader. The standard curve based on standard proteins was available by plotting 
average blank-adjusted readout versus concentration (µg/mL).   
2.2.8.3 Immunoblotting 
2.2.8.3.1 Polyacrylamide gel preparation 
Glass, as well as spacers, were cleaned using ethanol and deionized water. Clean 
glass sheets were assembled with spacers on a flat desktop. 10mL resolving gel 
solution (Table 3) was poured into the glass sheets with spacers. The resolving gel 
was overlaid with isopropanol and left for 20-30min at RT to keep a flat and horizontal 
surface. Overlaid isopropanol on resolving gel was then discarded, and stacking gel 
solution (Table 3) was added until it spilled over. A comb was instantly inserted without 
air bubbles between the gel and comb. It will take around 30min at RT to set gel.  
2.2.8.3.2 Polyacrylamide gel electrophoresis 
Samples including equivalent volumes of proteins (20μg/lane), including a weighted 
marker in one of the lanes, were carefully pipetted to SDS-PAGE wells. Electrophoresis 
equipment was added with running buffer (1x, see Table 3) according to the 





2.2.8.3.3 Membrane transfer 
Methanol was applied to stimulate PVDF membranes for 25s to get stimulated. 
Membranes were soaked in transfer buffer for use (1x, see Table 3). The membranes 
were dealt with carefully using a rounded tweezer to avoid scratching or puncturing the 
surface. Filter papers and sponges were put into transfer buffer 5min before “sandwich” 
creation. Following electrophoresis, the gel was separated from the machine for the 
transfer sandwich preparation. The sandwich layers were sequentially assembled, 
carefully getting rid of any air bubbles with a pipette since they will interrupt the 
procedure of protein transfer. Finally, the sandwich was put in the transfer container, 
and a wet transfer was conducted as instructed by the manufacturer’s protocol. 
2.2.8.3.4 Immunoblotting 
Following the transfer, TBST (1x) was applied to wash membranes three times. 
Blocking solution (Table 3) was utilized to incubate membranes overnight with 
continuous shaking (4˚C). Primary mAb solution was made by diluting to working 
concentration as recommended by the manufacturer’s protocol in TBST (1x) with 1% 
milk. The membranes were put into primary mAb solution with gently shaking (2h, RT). 
The membranes were placed in a secondary antibody solution (mild rocking, 1h, RT). 
Lastly, membranes were ready for detection following three washes. 
2.2.8.3.5 Detection 
According to the manufacturer's guidelines, the membrane was incubated for 3min in 
the ECL substrate, made before use. Hereafter, it was exposed to autoradiography film 
in a dark room. The grey values of bands were calculated by image J and used for 





Table 3 Solution formula in WB 
Solution Chemicals Doses 
Resolving gel solution deionized water (DIW) 3.8mL 
 1.5M Tris-HCl (pH 8.8) 2.6mL 
 30% Arc 3.4mL 
 10% SDS 0.1mL 
 TEMED 0.01mL 
 10% APS 0.1mL 
Stacking gel solution DIW 5.86mL 
 1.5M Tris-HCl (pH 6.8) 2.6mL 
 30% Arc 1.34mL 




 TEMED 0.01mL 
 10% APS 0.1mL 
Running Buffer (10x) Tris Base 30g 
 Gly 144g 
 SDS 10g 
 DIW 1L 
Running Buffer (1x) Running Buffer (10x) 0.1mL 
 DIW 0.9mL 
Transfer Buffer (10x) Tris Base 30g 
 Gly 144g 
 DIW 1L 
Transfer Buffer (1x) Transfer Buffer (10x) 0.1L 




 DIW 0.8L 
TBS (10x) Tris Base 24g 
 NaCl 80g 
 DIW 1L 
 PH 7.6 
TBST (1x) TBS (10x) 0.1L 
 DIW 0.9L 
 Tween 20 1mL 
Protein lysis Buffer RIPA buffer 0.1L 
 Protease inhibitor One tablet 
Tris-HCl (1M) solution Tris-base 12.12g 
 DIW 0.2L 




Tris-HCl (1.5M) solution Tris-base 36.34g 
 DIW 0.2L 
 PH 8.8 
Loading buffer loading buffer (4x) 0.9mL 
 β-Mercaptoethanol 0.1mL 
SDS solution (10%) SDS 10g 
 DIW 0.1L 
APS solution (10%) APS 10g 
 DIW 0.1mL 
Blocking solution Milk powder 1g 







2.2.9. Statistical Analysis 
SPSS 21.0 package was applied in all statistical analyses. The standard deviation of 
the mean (SD) represented the variance of mean values. Student t-test was used in 
the determination of differences between groups. Data in figures were exhibited as 
mean±SD of minimum triplicate or independent experiments. Chi-Squared tests were 
utilized to evaluate the correlation between VDR and αSMA expression. P-value (<0.05) 

















3.1. Establishment, verification of isolation of both activated 
and quiescent PSCs 
3.1.1 Establishment of PSCs isolation 
Using the outgrowth method, the cancer-associated PSCs (caPSCs) and chronic 
pancreatitis-associated PSCs (cpPSCs) were isolated from fibrotic parts of the 
pancreas, which were resected from PDAC or CP patients. The activated PSCs 
(caPSCs and cpPSCs) emerged from tissue blocks 3-5 days after seeding in the 
uncoated plastic cell culture plates (Figure 3A, Table 3). Morphologically, the activated 
PSCs showed a myofibroblast-like phenotype with a star-like shape and no lipid 
droplets inside (Figure 3A). 
 
 
Figure 3: Activated or quiescent PSCs were isolated using different methods. 
Representative photos: (A) with the outgrowth method, typical activated PSCs emerged from 
tissue block 3-5 days after seeding. Magnifications (x100). (B) nPSCs were isolated from 





However, no normal PSCs (nPSCs) grew out from normal pancreas tissue block using 
the outgrowth method, and this was similar to the result of Bachem’s[39]. The nycodenz 
density centrifugation method, described by Apte[38], was then utilized in histologically 
confirmed normal pancreatic tissues, and the yield of nPSCs was regularly 0.3-
1.6x106/g (Figure 3B, Table 3). The viability of all three kinds of PSCs was over 90% 
as evaluated with trypan blue staining (Table 3).  
Table 3 Details of isolated PSCs from different tissue types 
 Normal pancreas Pancreatic cancer Chronic pancreatitis 
Isolation method Density centrifugation Outgrowth Outgrowth 
Tissue weight (g) 0.14-3.52 0.2-1.22 0.36-1 
Isolation times 35 8 6 
Yield (x 106/g) 0.3-1.6 / / 
Emerging Timepoint / 3-5 days 3-5 days 
Viability >90% >90% >90% 
Doubling time 29.9±4.1h 27.7±3.7h 28.6±3.7h 
“/”: For PSCs isolated from pancreatic cancer and chronic pancreatitis, it's unable to measure the yield directly 
because activated PSCs slowly emerge from tissue block and proliferate over time. For PSCs isolated from the 
normal pancreas, emerging timepoint is not applicable as PSCs are isolated directly from tissue block, and the 







Morphologically, freshly separated nPSCs indicated an irregular shape with abundant 
perinuclear lipid droplets (Figure 4A), similar to the previous report by Apte in 1998[38]. 
After treated with trypsin for the 1st passage, all nPSCs transformed into the activated 
myofibroblast phenotype, which lost typical lipid droplets and showed a stellate-like 
shape (Figure 4B). nPSCs that subsequently passed during culture appeared not 




Figure 4: Morphology change in PSCs activation. Representative photos: (A) Newly isolated 
PSCs showed a quiescent phenotype that exhibited an irregular polygonal appearance with 
perinuclear lipid droplets (asterisks). (B) After the first passage, nPSCs turned into an activated 
phenotype that lost lipid droplets and changed into star-shaped cells.  
 
It was observed that most nPSCs attached to the flasks between 20h and 36h following 
seeding. The doubling time of the different kinds of PSCs (established from 5 separate 
nPSCs, caPSCs, and cpPSCs, between 3rd and 5th passage) was 29.9±4.1h, 
27.7±3.7h, and 28.6±3.7h, respectively (Table 3, Figure 5). Therefore, no difference in 




Figure 5: Growth curve of three different kinds of PSCs. The doubling time of nPSCs 
(A), caPSCs (B), cpPSCs (C) was 29.9±4.1h, 27.7±3.7h, and 28.6±3.7h, respectively.  
Compare to the data reported by other papers[8, 38, 39, 119], the results presented in our 
study are similar in terms of cell morphology, yield, viability, and growth curve. Overall, 
both the density centrifugation method for quiescent PSCs and the outgrowth method 








3.1.2 PSCs verification 
αSMA has already been widely recognized as an excellent marker of activated PSCs 
both in-vitro and in-vivo[6, 38, 39, 42, 119]. In this part, cells were further verified as PSCs 
using immunocytochemistry staining for the PSCs activation marker αSMA and 
selective marker desmin between passages 1 and 3.  
It was noticed that αSMA with immunocytochemistry staining showed the strongest 
immunoreactivity as 100% of cells indicated strong cytoplasmic positivity (Figure 6B), 
which further supported the opinion that αSMA was a perfect marker of activated 
PSCs[6, 43]. In comparison, 40-55% of cells showed a cytoplasmic positivity for desmin 
(Figure 6C), consistent with previous research that desmin was not expressed in all 
activated PSCs[38, 39]. 
 
Figure 6: Isolated cells were confirmed as PSCs by ICC staining of PSCs activation 
marker αSMA and selective marker desmin. Representative photos: (A) negative control. 
Magnifications (x100). (B) ICC observed positive staining of αSMA in PSCs (passage 1). 
Magnification (x100). (C) Positive staining for desmin by ICC in PSCs (passage 1). 
Magnification (x100). 
In conclusion, with the ICC staining of the widely accepted PSCs activation marker 
αSMA, the isolated cells are confirmed as PSCs with high purity in this project. The 





3.2. Expression of VDR is higher in caPSCs than PCCs 
There were already several pieces of research showing that mouse cpPSCs highly 
expressed VDR in the mouse chronic pancreatitis model[79, 120, 121]. However, little 
evidence about VDR expression of caPSCs and PCCs was found in human pancreatic 
cancer. This project assessed the VDR mRNA level and activity of this receptor in 
human caPSCs and PCCs. 
VDR expression was evaluated by qRT-PCR in 3 caPSCs samples and 3 PCCs 
(AsPC-1, MIA PaCa-2, PANC-1). In Figure 7A-B, caPSCs showed a relatively higher 
VDR expression than PCCs (p=0.014). For the VDR activity evaluation, 100nM 
calcipotriol (cal), a potent vitamin D analog [79], was applied to stimulate VDR for 48h. 
CYP24A1, markedly inducible when the VDR ligand binds to VDR[122], was assessed 
by qRT-PCR as a readout for activation of VDR. After the treatment of the VDR ligand, 
caPSCs consistently responded to the VDR ligand and expressed higher CYP24A1 
than the control group (p=0.001). However, PDAC lines showed a typically low VDR 
activity and low CYP24A1 expression after VDR ligand treatment (p=0.145) (Figures 
7C-D). 
These findings demonstrated that caPSCs showed a relatively high expression of VDR 













Figure 7: CaPSCs expressed higher VDR and reacted to Cal, while PCCs exhibited lower 
VDR and activity.  
(A)(B) qRT-PCR was utilized to evaluate VDR expression in three PCCs and three caPSCs. 
(unpaired t-test, * p<0.05). (C)(D) Indicated PCCs or PSCs with DMSO or Cal (100nM, 48h). 
qRT-PCR was applied to assess CYP24A1 expression, and values were normalized to GAPDH. 




3.3. VDR induction by its ligand decreases the PSCs activation  
Several pieces of research on hepatic fibrosis have verified that VDR induction 
decreased fibrosis, which was mainly caused by activated HSCs[11, 12, 14]. In addition, 
VDR ligand induction in fibroblast was reported to reduce lung fibrosis[10, 123] and renal 
fibrosis[13, 124, 125]. These researches inspired us to hypothesize that VDR might have 
the potential of deactivating PSCs and reducing fibrosis. This part will mainly explore 
the functions of this druggable receptor in PSCs activation. 
3.3.1. Vitamin D analog reduces αSMA expression in PSCs  
We respectively conducted ICC, WB, and qRT-PCR to investigate VDR’s role in PSCs 
activation.  
For the immunocytochemistry evaluation, caPSCs were incubated with 100nM Cal or 
vehicle (DMSO) for 48h, and αSMA staining was employed. The proportion of αSMA-
positive caPSCs was nearly 100% in the vehicle-treated group, while this proportion 
significantly decreased to 27% in the 100nM Cal-treated caPSCs group by ICC staining 
(p=0.000) (Figure 8). This result indicated that VDR induction by its ligand opposed 












Figure 8: VDR induction by its ligand reversed caPSCs activation evaluated by ICC. (A)(B) 
Representative photos: αSMA expression was measured by ICC in the three caPSC samples 
incubated with vehicle (A) or Cal (B) for 48h. (C) Quantification analysis of the proportion of 








WB was then performed to further confirmed the above result at the protein level. 
Compared to the control group, 100nM Cal-treated caPSCs showed a higher 
expression of VDR (p=0.003) and lower αSMA expression (p=0.004) in four caPSCs 
samples (Figure 9). This strongly supported our hypothesis that the activation 




Figure 9: VDR induction by 100nM Cal promoted caPSCs deactivation. (A) WB showed 
protein expression of VDR and αSMA in four caPSCs samples in the absence or presence of 
100nM Cal. (B)(C) Compared to the control group, 100nM Cal-treated caPSCs showed a higher 







Furthermore, this effect was evaluated in three different kinds of PSCs, and the 
correlation between VDR and αSMA was investigated at the mRNA level.  
qRT-PCR was conducted in three different kinds of PSCs (caPSCs, cpPSCs, nPSCs), 
treated with or without 100nM Cal. Similar to the results shown in ICC and WB, VDR 
mRNA expression significantly increased (p=0.002, 0.022, 0.024, respectively), while 
αSMA decreased in all three kinds of PSCs (caPSCs, cpPSCs, nPSCs) after 100nM 
Cal treatment (p=0.012, 0.001, 0.005, respectively)(Figure 10A-B). Correlation 
analysis indicated that VDR was in a moderate negative correlation with αSMA 
expression (p=0.031, Pearson's r=0.641)(Figure 10C).  
Overall, VDR plays a significant role in the PSCs activation procedure. In addition, with 
the capability to decrease the activation of PSCs, VDR induction by its ligand is 















Figure 10: VDR and αSMA mRNA expression in 3 different kinds of PSCs treated with 
vehicle or 100nM Cal. (A)(B) qRT-PCR was applied to measure VDR and αSMA expression 
in caPSCs, cpPSCs, and nPSCs samples. (paired t-test, * p<0.05). (C) VDR was indicated to 













3.3.2. Vitamin D analog decreases migration ability of activated PSCs 
Migration ability was firstly reported as another feature of activated PSCs by Phillips in 
2003[126] and verified by several other researchers [127-130]. PSCs have been reported 
to have the ability to migrate in reaction to chemokines like PDGF[126]. In addition, PSCs 
showed the ability to migrate when exposed to cancer cell secretions[6]. We supposed 
that the VDR ligand decreases the migration ability of activated PSCs. Therefore, in 
this part, the WH test and transwell experiments were conducted to explore whether 
VDR induction by its ligand could influence the migration ability of caPSCs or not.  
In the wound healing assay, scratched caPSCs (5x105 cells/well) monolayers were 
cultured with 100nM Cal or vehicle, and photos were taken at different timepoints as 
described in 2.2.6. Figure 11 showed that, wound area of caPSCs treated with 100nM 
Cal healed slower than the untreated control group from 24h (p values for 12h, 24h, 
36h, 48h, 60h were 0.499, 0.010, 0.001, 0.000, 0.000, respectively). This result 












Figure 11: VDR ligand 
decelerated migration 
ability of caPSCs in WH 
assay.  The migration 
ability was evaluated by 
the WH test in caPSCs. 
caPSCs were treated 
with or without 100nM Cal 
as described in 2.2.6. 
Results were obtained by 
conducting independent 
experiments three times, 
and pictures were 
obtained under a light 
microscope at different 
time points (magnification: 














A Transwell migration assay was also conducted to confirm the result further. CaPSCs 
were firstly cultured in medium (1% FBS) for 24h, and 5x104 caPSCs were suspended 
in 200μL medium with 100nM Cal or vehicle and grown in upper chambers. 600μL 
DMEM/F12 (5% FBS), as a chemoattractant, was pipetted into lower chambers.  
As shown in Figure 12, 100nM Cal treated group showed a statistically significantly 
smaller number of cells that passed through the membrane than the control group after 
24h (p=0.000).  
 
Figure 12: VDR ligand reduced the migration ability of caPSCs in the transwell migration 
assay. (A) (B) Representative photos of transwell migration assay for caPSCs in the absence 
(left) or presence (right) of 100nM Cal. (C) Quantification of transwell migration experiment 
showed the effect of 100nM Cal on the migration capability of caPSCs. Photos were taken by 
light microscopy (x 200 magnification) after 24h. Quantification was conducted by calculating 




3.3.3. Vitamin D analog decreases proliferation ability of activated PSCs 
Proliferation ability is widely accepted as the feature of activated PSCs[8, 9, 131, 132]. 
Freshly isolated nPSCs from histologically normal pancreas and caPSCs from tumor 
tissue were cultured with 100nM Cal or DMSO in 96-well plates for 48h. EZ4U was 
applied to evaluate the proliferation ability of PSCs following the manufacturer´s 
protocol. As indicated in Figure 13, the VDR ligand reduced the proliferation ability of 




Figure 13: VDR induction decreased the proliferation of caPSCs but not that of nPSCs. 
nPSCs and caPSCs were incubated with or without 100nM Cal, and proliferation ability was 






3.4. VDR activation in caPSCs attenuates caPSCs-augmented 
progression of PCCs 
Several studies indicated that caPSCs enhanced the proliferation, migration, and 
invasion ability of PCCs[59, 133-135]. Therefore, we put forward the hypothesis that VDR 
activation in caPSCs might attenuate caPSCs-augmented proliferation, migration, and 
invasion ability of PCCs. Thus, in this part, we assessed the influence of VDR ligand-
stimulated caPSCs on the interplay between caPSCs and PCCs. 
3.4.1. VDR activation in caPSCs decreases caPSCs-augmented migration 
ability of PCCs 
To evaluate the impact of VDR activation in caPSCs on migration ability of PCCs, 
transwell migration experiments were carried out utilizing chambers without coated 
Matrigel. Three caPSCs were grown to confluency, followed by a 100nM Cal or DMSO 
treatment for 48h. The caPSCs above were co-cultured with the PCCs (AsPC-1, 
PANC-1, MIA PaCa-2) in a transwell co-culture system for 24h. As shown in Figure 14, 
PCCs co-cultured with deactivated caPSCs (pretreated with 100nM Cal) showed a 
weaker migration ability than the control (p=0.001, 0.000, 0.004). Results 
demonstrated that VDR-stimulated caPSCs decreased the caPSCs-augmented 




   
Figure 14: VDR activation in caPSCs decreased caPSCs-augmented PCCs migration. (A) 
Representative photos: three PDAC cell lines were co-cultured with three caPSCs samples 
(pretreated with or without 100nM Cal for 48h) in a transwell co-culture system for 24h. Cells 
migrating onto the lower side were stained using crystal violet. (B) PCCs co-cultured with 
deactivated caPSCs (pretreated with 100nM Cal) showed a weaker migration ability than the 




3.4.2. VDR activation in caPSCs decreases caPSCs-augmented invasion 
ability of PCCs 
To assess the effects of VDR activation in caPSCs on the invasion ability of PCCs, 
transwell invasion experiments were performed utilizing chambers coated with Matrigel. 
Three caPSCs were grown to confluency, followed by a 100nM Cal or DMSO treatment 
for 48h. The caPSCs above were co-cultured with the PCCs (mentioned in 3.4.1) were 
then co-cultured in a transwell co-culture system for 48h. As presented in Figure 15, 
PCCs cultured with deactivated caPSCs (pretreated with 100nM Cal) indicated a 
weaker invasion ability than that of control (p=0.000, 0.000, 0.000). The results proved 






Figure 15: VDR activation in caPSCs decreased caPSCs-augmented PCCs invasion. (A) 
Representative photos: three PDAC cell lines were co-cultured with three caPSCs samples 
(pretreated with or without 100nM Cal for 48h) in a transwell co-culture system for 48h. PCCs 
invading onto the lower side were stained using crystal violet. (B) PCCs cultured with 
deactivated caPSCs (pretreated with 100nM Cal) indicated a weaker invasion ability than 




3.4.3. VDR activation in caPSCs diminishes caPSCs-augmented 
proliferation ability of PCCs  
Finally, the effect of calcipotriol-treated caPSCs on the proliferation of PCCs was 
determined in accordance with the manufacturer´s protocol of the EZ4U assay. 
Three primary caPSCs were grown to confluency and incubated with 100nM Cal or 
vehicle for 48h. Conditioned medium (CM) from them was gathered and transferred to 
culture different PCCs grown in 96-well plates for 48h. Figure 16 showed that, CM from 
deactivated caPSCs (pretreated with 100nM Cal) significantly decreased proliferation 
ability of all three PCCs (p=0.007, 0.008, 0.002 for AsPC-1, PANC-1, MIA PaCa-2 
respectively). However, this effect was not observed in all three PCCs incubated with 
CM from the activated caPSCs, pretreated with vehicle (p=0.714, 0.304, 0.098 for 
PCCs mentioned above). Results showed that VDR activation in caPSCs negatively 











Figure 16: VDR activation in caPSCs decreased caPSCs-augmented PCCs proliferation. 
The PDAC cell lines were cultured in CM from three caPSCs samples (pretreated with or 
without 100nM Cal for 48h) in a 96-well plate for 48h. 20μL dye substrate was then pipetted 
into each well, followed by a 3h incubation. Absorbance as described in 2.2.4. (paired t-test, 







With well-established isolation technologies, VDR shows an essential role in caPSCs 
activation and caPSCs-induced PCCs aggressiveness in our project. Here we will 
make a detailed discussion based on our results and published literature.  
4.1. Isolation and verification of human PSCs 
First, efficient PSCs isolation and verification methods are certainly important for 
deeply researching PSCs’ role in PDAC and CP. Although immortalized PSCs were 
reported[133, 136], primary PSCs are still the main research tools [8]. As reported by the 
Pancreatic Star Alliance, M. Buchholz found that a single injection of immortalized 
PSCs to nude mice sometimes resulted in invasive anaplastic PDAC, demonstrating 
that immortalization technologies require improvement[8]. Although isolation methods 
for murine primary PSCs were developed in 1998 and very mature, literature also 
indicated that species variances exist between murine and human PSCs[8, 137]. 
Therefore, we used human primary PSCs, both activated and quiescent, in our 
research. The outgrowth method for human caPSCs and cpPSCs was invented in 
1998[39], while the density centrifugation method for human quiescent PSCs (nPSCs) 
was not developed until 2010[119]. Based on their great work on both methods, we 
further improved the isolation methods according to our practices and successfully 
established caPSCs, cpPSCs, and nPSCs in our lab. For the caPSCs and cpPSCs, 
we made improvement as follows: a) tissues were removed of adipose, connective 
section as well as blood before further processing because theses would lead to cell 
contaminations; b) the entire isolation process should be as soon as possible because 
cells would be dead after tissues were resected; c) due to the previous trimming 




medium but not the complex refreshment-reseeding procedure. As to the outcomes, 
emerging timepoint from tissue blocks, Bachem et al. reported a 3-5 days after seeding 
for cpPSCs[39], and we showed the same results in both cpPSCs and caPSCs with an 
over 90% viability. A similar result was also achieved: nPSCs could not grow out from 
normal pancreas tissue block using the outgrowth method[39]. Morphologically, the 
activated PSCs showed a star-shaped with no lipid droplets inside, consistent with the 
previous descriptions[37, 39]. For the density centrifugation method, a) the injection 
procedure[119] was omitted, and single 15-minute digestion in a shaking water bath 
accelerated the digestion procedure; b) 2.5μg/mL AmB was applied in the complete 
medium to avoid potential fungal contamination. Vonlaufen et al reported 0.2-1.4x106/g 
(n=5), and we have a similar yield of 0.3-1.6x106/g human nPSCs (n=5) with over 90% 
viability (Figure 3B, Table 3). Compared to the yield of rat nPSCs (about 3x106/g), 
human nPSCs have a relatively lower yield due to the higher proportion of fat, 
connective, and vascular tissues in the human pancreas. As to the morphology of 
human nPSCs, both the two published papers[119, 138] and we indicated that freshly 
separated human nPSCs indicated an irregular shape with abundant perinuclear lipid 
droplets, and following treatment with trypsin for the 1st passage, all nPSCs 
transformed into the activated phenotype, which lost lipid droplets and showed a 
stellate-like shape. In the verification of human PSCs, ICC staining of αSMA and 
desmin was utilized. ICC showed a 100% αSMA and 40-55% desmin staining, which 
were similar to the data from Bachem[39] (αSMA: >90% positive, desmin: 20%-50% 
positive), Tian[138] (αSMA: strong positive, desmin: partly positive) and Qian[60] (αSMA: 
positive, desmin: positive) on human PSCs[39]. This indicated that the human primary 
nPSCs, caPSCs, and cpPSCs were successfully established in our lab.  
In conclusion, based on other scientists’ outstanding work and our practices, the 
improved isolation methods in our lab have the advantage of more simplified steps 




4.2. VDR in PSCs activation process 
Four studies are found in investigating the effect of VDR ligand on PSCs activation[79, 
120, 121, 139]. This section will discuss our results and the published data to better 
understand VDR’s role in PSCs activation. 
To begin with, we checked the VDR expression and activity in caPSCs and PCCs and 
found that caPSCs exhibited a relatively higher expression of VDR and activity than 
PCCs. This finding is consistent with the previous data[79], both of which indicated that 
VDR is a promising druggable receptor in caPSCs.  
Then we conducted ICC, WB, and qRT-PCR to explore the effects of VDR ligand upon 
caPSCs with αSMA as the indicator of activation. Our ICC result showed that αSMA 
staining in caPSCs incubated with Cal significantly is stronger than the control group, 
which indicated an inhibitory effect of VDR ligand on activation of caPSCs. WB and 
qRT-PCR exhibited similar results in that VDR increased, whereas those of αSMA 
decreased after caPSCs were treated with VDR ligand. Sherman et al. showed that 
αSMA mRNA decreased and lipid droplets (the feature of quiescent PSCs) reformated 
after VDR ligand treatment[79]. Our findings, both at protein and mRNA levels, further 
confirmed the hypothesis that VDR induction by its ligand opposed the activation 
procedure of caPSCs. 
Additionally, we assessed this effect in cpPSCs and nPSCs (culture-activated) and 
further investigated the correlation between VDR and αSMA at the mRNA level. qRT-
PCR revealed that VDR mRNA increased whereas αSMA mRNA decreased in the two 
kinds of PSCs treated with VDR ligand compared to the control group. Unlike our study 
using human PSCs, cpPSCs and culture-activated nPSCs in the published papers 




reduced αSMA protein expression and prevented lipids loss in culture-activated murine 
nPSCs[139]. Kang et al. demonstrated that VDR ligand impeded αSMA expression using 
ICC assay in the CP mouse model[121]. All studies from human PSCs and murine 
showed that the VDR ligand diminished the PSCs activation. Moreover, we first 
reported that VDR was in a moderate negative correlation with αSMA expression using 
qRT-PCR, which further proved a critical role of VDR in the PSCs activation process. 
In addition, we first comprehensively investigated VDR’s effects on the activation of all 
three kinds of PSCs with human sources. 
Migration ability is a feature of activated PSCs, which enable PSCs to accumulate in 
disease regions[126-130]. caPSCs showed the ability of migration when exposed to 
cancer cell secretions[6]. No papers about the effects of VDR ligand upon caPSCs 
migration were published after literature searching. Therefore, we conducted a 
transwell migration experiment and WH test and found that the VDR ligand significantly 
decreased the migration ability of activated caPSCs. We explain that the VDR ligand 
diminishes the autocrine secretion of caPSCs which keeps themselves activated and 
enables them to migrate. 
As another feature of activated PSCs, proliferation ability combined with migration 
ability contributes to increased PSCs in diseases like CP and PDAC[8, 9, 131, 132]. EZ4U 
assay demonstrated that the VDR ligand reduced the proliferation ability of caPSCs, 
but not that of freshly isolated nPSCs. Blauer demonstrated that 1,25(OH)2D3 reduced 
the proliferation ability of culture-activated murine PSCs by colorimetric crystal violet 
assay. However, Wallbaum reported that VDR ligands have no effect on murine 
culture-activated nPSCs by BrdU assay. The possible reason for this difference might 
be PSCs with different sources, different monitoring methods, and different drug 




Overall, VDR plays a significant role in PSCs activation, migration, and proliferation. 
VDR ligand is expected to become a powerful tool to prevent the severe desmoplasia 
reaction of PDAC and improve PDAC therapy.  
4.3. VDR in caPSCs-augmented aggressiveness of PCCs 
Previous works have indicated that caPSCs release various molecules, enhancing the 
aggressiveness (e.g., migration, invasion, proliferation) of PCCs[51, 55, 92, 134, 140-144]. 
Targeting the paracrine crosstalk has become hotspots in researches on anti-PSCs 
strategy recently. However, little evidence was found about the effects of VDR ligand 
on caPSCs-PCCs crosstalk.  
Since the VDR ligand could inhibit the caPSCs activation, we hypothesized that 
caPSCs deactivated by the VDR ligand released fewer molecules, leading to less 
aggressiveness of PCCs. Therefore, we cocultured three caPSCs and three PCCs in 
the transwell system and found that both migration and invasion abilities of PCCs were 
impeded when cocultured with deactivated caPSCs. We explain that the VDR ligand 
inhibits caPSCs activation as well as reducing tumorigenic molecule secretion. 
We then assessed the proliferation ability of three PCCs using CM from three caPSCs, 
respectively. EZ4U showed that CM from caPSCs deactivated by VDR ligand 
significantly decreased the proliferation ability of all three PCCs. Results showed that 
VDR activation in caPSCs negatively regulated the caPSCs-augmented proliferation 
of PCCs. The paracrine molecules, which promote PCCs proliferation, might be 
inhibited by VDR ligand in caPSCs 
In summary, we indicated the VDR ligand as a potential target to reduce the caPSCs-





4.4. Conclusion and Outlook  
In conclusion, VDR activation by its ligand deactivated caPSCs and then diminished 
caPSCs-enhanced PDAC aggressiveness. Our work indicated that VDR is a potential 
anti-stroma method for PDAC therapy. 
In future work, we are going to explore the deep mechanism further. This may include 
but is not limited to: a) identify the potential molecules influenced by VDR ligand and 
play a role in the caPSCs-PCCs crosstalk. b) the mechanisms by which these caPSCs-
secreted molecules influence the aggressiveness of PCCs and how the VDR ligand 
will attenuate this effect. c) further verification in an animal model or PDAC organoid 













The dismal prognosis of PDAC owns to a pro-tumorigenic stroma which occupies most 
(50%-80%) of tumor volume and increases chemoresistance. PSCs transformation 
from quiescent to activated phenotype is the leading cause of the severe stromal 
reaction. Since standard chemotherapy has displayed disappointing outcomes, stroma 
targeting strategy and chemotherapy have become the research hotspot. VDR has 
been well investigated in hepatic fibrosis caused by activated HSCs and emerged as 
a promising anti-stroma target in PDAC therapy. This project is devoted to exploring 
the role of VDR on PSCs deactivation and caPSCs-PCCs crosstalk in vitro, which 
would provide an anti-stromal target for PDAC treatment. 
The technique to isolate both the quiescent PSCs from the normal pancreas and the 
activated PSCs from tumor tissue of patients suffering from PDAC or chronic 
pancreatitis was established and verified by ICC. VDR was revealed to be highly 
expressed in caPSCs as opposed to PCCs. VDR induction by calcipotriol, a vitamin D 
analog, markedly reduced caPSCs activation markers at mRNA and protein levels. 
This decreased caPSCs activation by VDR induction through calcipotriol diminished 
the proliferation of caPSCs. In addition, caPSCs migration was also reduced after VDR 
stimulation in both WH assay and transwell migration assays. In the caPSCs-PCCs 
co-culture system, VDR activation in caPSCs significantly reduced caPSCs-
augmented progression of pancreatic tumor cells, including migration, invasion, and 
proliferation utilizing transwell migration, invasion, and EZ4U assay, respectively.  
In conclusion, VDR induction by its ligand deactivated caPSCs and reduced caPSCs-
augmented PDAC progression. This work suggested VDR as a promising target for 





Das Pankreaskarzinom ist durch eine ausgeprägte stromale Beteiligung 
gekennzeichnet bei dem der stromalen Anteil in der Regel die Mehrheit (50-80%) des 
Tumorvolumens ausmacht. Aktivierte pankreatische Stellatumzellen (PSCs) spielen 
eine entscheidende Rolle bei der Fibrogenese und stimulieren das 
Tumorzellwachstum. Nachdem konventionelle Chemotherapeutika beim 
Pankreaskarzinom bisher eher enttäuschende Ergebnisse gezeigt haben, ist nun die 
Frage entstanden ob nicht durch eine zusätzliche Modifikation des Stromas bessere 
anti-tumorale Wirkungen erzielt werden können. Der Vitamin-D Rezeptor VDR ist bei  
aktivierten hepatischen Sternzellen und der Leberfibrose gut untersucht und stellt auch 
in der anti-stromalen Therapie beim Pankreaskarzinom ein vielversprechendes Ziel 
dar.  
In dieser Arbeit wurde zunächst die Isolation von primären Stellatumzellen (sowohl 
aktivierte als auch Ruhe-PSCs) aus Geweben von Patienten mit Pankreaskarzinom 
oder chronischer Pankreatitis etabliert und mittels der Immunzytologie weiter verifiziert. 
Hierbei fiel auf, dass der Vitamin-D Rezeptor VDR in PSCs, also im Stroma von 
Patienten mit Pankreaskarzinom höher exprimiert werden als in den primären 
Tumorzellen. Eine VDR Stimulation durch das potente Vitamin D Analogon Calcipotriol 
reduzierte den Aktivierungszustand dieser PSCs deutlich. Diese stimulierten, und 
damit weniger aktivierten PSCs zeigten funktionell auch eine deutlich verminderte 
Migration und Proliferation. Darüber hinaus zeigte sich in der Co-Kultur eine signifikant 
verminderte Proliferation, Migration und Invasion der Pankreaskarzinomzellen, wenn 
Sie mit Calcipotriol vorbehandelten PSCs co-kultiviert wurden.  
Zusammenfassend konnte in der vorliegenden Arbeit gezeigt werden, dass eine 




weniger aktivierten PSCs und somit indirekt zu einem weniger aggressiven Verhalten 
der Pankreaskarzinomzellen in vitro führt. Der Vitamin D Rezeptor VDR stellt somit ein 
vielversprechendes Ziel für eine anti-tumorale Modifikation des Stromas beim 
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